Wenli Gou
Overview
Explore the profile of Wenli Gou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
145
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huang P, Song Y, Yang Y, Bai F, Li N, Liu D, et al.
Front Immunol
. 2024 Jan;
14:1304165.
PMID: 38259465
Preeclampsia is one of the leading causes of maternal and fetal morbidity and mortality worldwide. Preeclampsia is linked to mitochondrial dysfunction as a contributing factor in its progression. This study...
2.
Wu L, Yao H, Chen H, Wang A, Guo K, Gou W, et al.
Nat Commun
. 2022 Jul;
13(1):4264.
PMID: 35871175
Extending the benefits of tumor molecular profiling for all cancer patients requires a comprehensive analysis of tumor genomes across distinct patient populations worldwide. In this study, we perform deep next-generation...
3.
Gao J, Huang X, Di W, Dong X, Gou W, Shi H, et al.
Front Cardiovasc Med
. 2021 Sep;
8:602560.
PMID: 34497833
The diagnosis of preeclampsia in China currently relies on limited clinical signs and unspecific laboratory findings. These are inadequate predictors of preeclampsia development, limiting early diagnosis and appropriate management. Previously,...
4.
Li C, Gou W, Liu J, Liu D, Li X, Chen Q
J Hum Hypertens
. 2021 Apr;
36(2):201-206.
PMID: 33846545
To date, data on postpartum management of preeclampsia including the optimal time for discharge are limited. The aims of this study were to investigate the appropriate time for discharge after...
5.
Fu J, Li C, Gou W, Lee A, Li X, Chen Q
J Hum Hypertens
. 2019 Feb;
33(9):664-670.
PMID: 30745577
Today the only effective "treatment" for preeclampsia is to deliver at the optimal time for both maternal and foetal well-being. Studies reported that severe preeclampsia can benefit from the expectant...
6.
Zong L, Wei X, Gou W, Huang P, Lv Y
Oncotarget
. 2018 Feb;
8(70):115190-115201.
PMID: 29383152
Fetal growth restriction (FGR) is a well-known risk factor for cognitive dysfunction, especially for learning and memory abilities. However, knowledge about prevention and treatment methods of learning and memory abilities...
7.
Dong X, Gou W, Li C, Wu M, Han Z, Li X, et al.
Pregnancy Hypertens
. 2017 May;
8:60-64.
PMID: 28501282
Preeclampsia is a leading cause of maternal and perinatal morbidity and mortality globally and proteinuria can be one of the cardinal features of this disease. However, studies about the association...
8.
Wang L, Li X, Zhao Y, Fang C, Lian Y, Gou W, et al.
Acta Biochim Biophys Sin (Shanghai)
. 2015 Jul;
47(9):663-72.
PMID: 26188201
The chemokine CXCL12 and its receptor CXCR4 are important signaling components required for human blastocyst implantation and the progression of pregnancy. Growing evidence indicates that the CXCL12/CXCR4 axis can regulate...
9.
Li L, Li X, Han X, Yang T, Fu J, Zhang Y, et al.
Oncol Rep
. 2014 Jun;
32(3):943-50.
PMID: 24968896
Approximately 60% of ovarian cancers are positive for the estrogen receptor (ER); however, ER-targeted treatment is disappointing due to drug resistance as compared with breast cancer. In estrogen-sensitive cancers, estrogen...
10.
Li X, Li C, Dong X, Gou W
Mol Med Rep
. 2014 May;
10(1):550-4.
PMID: 24806148
The aim of the present study was to characterize the role of microRNA (miR)-155 in the pathogenesis of severe preeclampsia (PE). A total of 19 severe preeclampsic and 22 normal...